Logo
x

Search

Subscribe Now

Acute Myeloid Leukemia

BMS' Onureg (azacytidine) Receives EC's Approval for as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia

BMS' Onureg (azacytidine) Receives EC's Approval for as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia

  • June 21, 2021
AbbVie's Venclyxto Receives the EC's Approval for Patients with Newly Diagnosed Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy

AbbVie's Venclyxto Receives the EC's Approval for Patients with Newly Diagnosed Acute Myeloid Leukemia who are Ineligible for Inte...

  • May 26, 2021
Daiichi Sankyo Reports First patient Dosing in P- I/II Trial of DS-1594 to Treat Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Daiichi Sankyo Reports First patient Dosing in P- I/II Trial of DS-1594 to Treat Acute Myeloid Leukemia and Acute Lymphoblastic Le...

  • April 8, 2021
AbbVie and Roche's Venclexta (venetoclax) Receive the US FDA's Approval for Acute Myeloid Leukemia

AbbVie and Roche's Venclexta (venetoclax) Receive the US FDA's Approval for Acute Myeloid Leukemia

  • October 19, 2020
Kite and HiFiBiO Therapeutics Collaborate to Develop Antibodies Targeting Acute Myeloid Leukemia

Kite and HiFiBiO Therapeutics Collaborate to Develop Antibodies Targeting Acute Myeloid Leukemia

  • September 4, 2020
BMS' Onureg (azacitidine) Receives the US FDA's Approval as Continued Treatment for Acute Myeloid Leukemia

BMS' Onureg (azacitidine) Receives the US FDA's Approval as Continued Treatment for Acute Myeloid Leukemia

  • September 2, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.